European consensus table on the use of botulinum toxin type A in adult spasticity.

A group of clinicians from across Europe experienced in the use of botulinum toxin type A for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. This consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. Published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

[1]  C. Pozzilli,et al.  Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis , 2007, Clinical rehabilitation.

[2]  J. Espadaler,et al.  Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. , 2007, Journal of rehabilitation medicine.

[3]  M. V. von Arbin,et al.  Spasticity After Stroke: Its Occurrence and Association With Motor Impairments and Activity Limitations , 2003, Stroke.

[4]  Richard Greenwood,et al.  Evaluating the role of botulinum toxin in the management of focal hypertonia in adults , 2000, Journal of neurology, neurosurgery, and psychiatry.

[5]  M. Brin,et al.  Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. , 2007, Clinical therapeutics.

[6]  J. van Limbeek,et al.  Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. , 2002, Journal of rehabilitation medicine.

[7]  B. Bioulac,et al.  A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[8]  M. Leathley,et al.  Prevalence of spasticity post stroke , 2002, Clinical rehabilitation.

[9]  R. Young,et al.  Spasticity, disordered motor control , 1980 .

[10]  A. Suputtitada,et al.  The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity , 2005, Disability and rehabilitation.

[11]  G. Caty.  Effect of high dose Botulinum Toxin injection on impairment, activity and participation among stroke patients presenting with a stiff-knee gait. , 2007 .

[12]  B. Bhakta,et al.  The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  E. Elovic,et al.  Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. , 2002, The New England journal of medicine.

[14]  M. Brin,et al.  Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity , 1997, Muscle & nerve. Supplement.

[15]  Werner Poewe,et al.  A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke , 2000, Stroke.

[16]  B. Bhakta,et al.  Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial , 2000, Journal of neurology, neurosurgery, and psychiatry.

[17]  J. W. Archer,et al.  The Estimated Cost of Managing Focal Spasticity: A Physician Practice Patterns Survey , 2001, Neurorehabilitation and neural repair.

[18]  J. Dolly,et al.  The structure and mode of action of different botulinum toxins , 2006, European journal of neurology.

[19]  Pamela W Duncan,et al.  Management of Adult Stroke Rehabilitation Care: a clinical practice guideline. , 2005, Stroke.

[20]  D. M. Simpson,et al.  Botulinum toxin type A in the treatment of upper extremity spasticity , 1996, Neurology.

[21]  Symposium synopsis , 1986 .

[22]  A. Priori,et al.  Nerve stimulation boosts botulinum toxin action in spasticity , 2005, Movement disorders : official journal of the Movement Disorder Society.

[23]  H. Shill,et al.  Accuracy of muscle localization without EMG: Implications for treatment of limb dystonia , 2002, Neurology.

[24]  R. Young.  Spasticity: A review , 1994, Neurology.

[25]  P. Charles,et al.  Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. , 2007, Clinical therapeutics.

[26]  S. Gillard,et al.  Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. , 2005, Journal of rehabilitation medicine.

[27]  David M Simpson,et al.  Anatomical Localization of Motor Endplate Bands in the Human Biceps Brachii , 2007, Journal of clinical neuromuscular disease.

[28]  J. Kornegay,et al.  Evaluating motor end‐plate‐targeted injections of botulinum toxin type A in a canine model , 1998, Muscle & nerve.

[29]  N. Paik,et al.  Intramuscular Botulinum Toxin-A Reduces Hemiplegic Shoulder Pain: A Randomized, Double-Blind, Comparative Study Versus Intraarticular Triamcinolone Acetonide , 2008, Stroke.

[30]  R. Dworkin,et al.  The impact of neuropathic pain on health-related quality of life , 2007, Neurology.

[31]  S. Hesse,et al.  Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial , 1998, Clinical rehabilitation.

[32]  L. Turner-Stokes,et al.  Goal attainment for spasticity management using botulinum toxin. , 2006, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[33]  Sonographic Imaging for Guiding Botulinum Toxin Injections in Limb Muscles , 2004 .

[34]  E. Vicaut,et al.  Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  A. Geurts,et al.  Are clinical characteristics associated with upper-extremity hypertonia in severe ischaemic supratentorial stroke? , 2007, Journal of rehabilitation medicine.

[36]  Y. Kirazlı,et al.  Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. , 1998, American journal of physical medicine & rehabilitation.

[37]  N. Bathien,et al.  Botulinum antibodies in dystonic patients treated with type A botulinum toxin , 1993, Neurology.

[38]  S. Smith,et al.  A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury , 2000, Clinical rehabilitation.

[39]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[40]  A. Ward,et al.  A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury , 2005, Clinical rehabilitation.

[41]  G. Nappi,et al.  A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot , 2005, Neurological Sciences.

[42]  L. Provinciali,et al.  Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. , 2000, American journal of physical medicine & rehabilitation.

[43]  S. Fahn,et al.  Development of Antibodies to Botulinum Toxin Type A in Patients with Torticollis Treated with Injections of Botulinum Toxin Type A , 1993 .

[44]  F. Heinen,et al.  Sonography-Guided Injection of Botulinum Toxin A in Children with Cerebral Palsy , 2002, Lancet.

[45]  S. Otto,et al.  A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke , 2001, European journal of neurology.

[46]  K. De Boulle,et al.  Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. , 2007, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[47]  M. Leathley,et al.  Predicting spasticity after stroke in those surviving to 12 months , 2004, Clinical rehabilitation.

[48]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[49]  E. Elovic,et al.  Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke , 2004, Neurology.

[50]  J. Wissel,et al.  Using translational medicine to understand clinical differences between botulinum toxin formulations , 2006, European journal of neurology.

[51]  C. Detrembleur,et al.  Effect of Simultaneous Botulinum Toxin Injections Into Several Muscles on Impairment, Activity, Participation, and Quality of Life Among Stroke Patients Presenting With a Stiff Knee Gait , 2008, Stroke.

[52]  Christine Detrembleur,et al.  Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. , 2008, Archives of physical medicine and rehabilitation.

[53]  M. Reding,et al.  Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. , 2004, Archives of physical medicine and rehabilitation.

[54]  S Fahn,et al.  Development of resistance to botulinum toxin type A in patients with torticollis , 2004, Movement disorders : official journal of the Movement Disorder Society.

[55]  G. Molenaers,et al.  Safety and efficacy of botulinum toxin type A following long‐term use , 2006, European journal of neurology.

[56]  J. Gracies,et al.  Pathophysiology of spastic paresis. II: Emergence of muscle overactivity , 2005, Muscle & nerve.

[57]  L. Turner-Stokes,et al.  Botulinum toxin in the management of spasticity in adults. , 2002, Clinical medicine.

[58]  Jean-Michel Gracies,et al.  Pathophysiology of spastic paresis. I: Paresis and soft tissue changes , 2005, Muscle & nerve.

[59]  M. Jan,et al.  Prediction of infarct topography using the Oxfordshire Community Stroke Project classification of stroke subtypes. , 1998, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[60]  S. Carda,et al.  Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case—control study , 2005, Clinical rehabilitation.

[61]  N. Hyman,et al.  Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[62]  R. Lucena,et al.  Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. , 2005, Arquivos de neuro-psiquiatria.

[63]  H. Bigalke,et al.  Botulinum neurotoxin — from laboratory to bedside , 2006, Neurotoxicity Research.

[64]  D B Calne,et al.  Treatment of spasticity with botulinum toxin: A double‐blind study , 1990, Annals of neurology.

[65]  C. Sampaio,et al.  Clinical comparability of marketed formulations of botulinum toxin , 2004, Movement disorders : official journal of the Movement Disorder Society.

[66]  Florian Heinen,et al.  Sonography-guided injection of botulinum toxin in children with cerebral palsy , 2004, The Lancet.

[67]  O. Hardiman,et al.  A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport®) in the Treatment of Spastic Equinovarus Deformity after Stroke , 2003, Cerebrovascular Diseases.

[68]  J. Gaddum,et al.  The Pharmacological Basis of Therapeutics , 1966 .

[69]  J. Jankovic,et al.  Long‐term botulinum toxin efficacy, safety, and immunogenicity , 2005, Movement disorders : official journal of the Movement Disorder Society.

[70]  M. Hallett,et al.  Effect of muscle activity immediately after botulinum toxin injection for writer's cramp , 1999, Movement disorders : official journal of the Movement Disorder Society.

[71]  Eric A. Johnson,et al.  SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.

[72]  F. Molteni,et al.  Use of botulinum toxin type A in management of adult spasticity--a European consensus statement. , 2004, Journal of rehabilitation medicine.

[73]  B. Jabbari,et al.  Botulinum toxin A for spasticity, muscle spasms, and rigidity , 1995, Neurology.

[74]  H. Graham,et al.  Accuracy of Intramuscular Injection of Botulinum Toxin A in Juvenile Cerebral Palsy: A Comparison Between Manual Needle Placement and Placement Guided by Electrical Stimulation , 2005, Journal of pediatric orthopedics.

[75]  I. Sanders,et al.  Quantifying how location and dose of botulinum toxin injections affect muscle paralysis , 1993, Muscle & nerve.

[76]  D. Wade,et al.  Does reducing spasticity translate into functional benefit? An exploratory meta-analysis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[77]  J. Jankovic,et al.  Safety of botulinum toxin type A: a systematic review and meta-analysis , 2004, Current medical research and opinion.

[78]  K. Mauritz,et al.  Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients , 1995, Neuroscience Letters.

[79]  R. Nudo,et al.  Neural Substrates for the Effects of Rehabilitative Training on Motor Recovery After Ischemic Infarct , 1996, Science.